Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 19/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 8/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SSTR1 | P30872 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-7145 SCHEMBL2894677 | 1.00 | KCNJ1 (1.00) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| Mk-7145 SCHEMBL297123 | 1.00 | KCNJ1 (1.00) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| Mk-7145 SCHEMBL2894681 | 1.00 | KCNJ1 (1.00) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| Mk-7145 SCHEMBL297586 | 1.00 | KCNJ1 (1.00) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| Mk-7145 SCHEMBL2898237 | 0.99 | KCNJ1 (0.97) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| Mk-7145 SCHEMBL2897265 | 0.99 | KCNJ1 (0.97) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| Mk-7145 SCHEMBL2899446 | 0.97 | KCNJ1 (0.95) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL16169896 | 0.96 | KCNJ1 (0.93) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| SCHEMBL2897116 | 0.96 | KCNJ1 (0.93) | KCNJ1KCNH2ACHESSTR1SLC6A4 | |
| Mk-7145 SCHEMBL2897745 | 0.95 | KCNJ1 (0.91) | KCNJ1KCNH2ACHESSTR1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106002-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20220168243-A1 | CORONAVIRUS TREATMENT COMPOSITIONS AND METHODS | UNIV NEW YORK STATE RES FOUND (US) | 2022-06-02 | — | — | US | disclosed |
| EP-3998260-A1 | SGC STIMULATORS | Cyclerion Therapeutics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106002-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | KCNJ1 726/4885KCNH2 1375/4885ACHE 1871/4885 |
| US-20220168243-A1 | CORONAVIRUS TREATMENT COMPOSITIONS AND METHODS | ACE, SARS1, ACE2 | KCNJ1 4387/4885KCNH2 3908/4885ACHE 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.